PERRIGO COMPANY PLC (PRGO) is a publicly traded Healthcare sector company. As of May 21, 2026, PRGO trades at $11.16 with a market cap of $1.48B and a P/E ratio of -0.85. PRGO moved +5.23% today. Year to date, PRGO is -21.24%; over the trailing twelve months it is -59.30%. Its 52-week range spans $9.23 to $30.93. Analyst consensus is buy with an average price target of $16.00. Rallies surfaces PRGO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Perrigo Q1 Net Sales Down 7.2% to $969M, €306M Divestiture Boosts Debt Reduction: Perrigo’s Q1 continuing operations net sales fell 7.2% to $969 million while Core organic sales declined 11.0%, driven by lower seasonal cough/cold demand and retailer destocking. The company secured €306 million from its Dermacosmetics divestiture for debt reduction, took a $330.8 million goodwill impairment and upheld full-year 2026 guidance.
| Metric | Value |
|---|---|
| Price | $11.16 |
| Market Cap | $1.48B |
| P/E Ratio | -0.85 |
| EPS | $-13.12 |
| Dividend Yield | 0.01% |
| 52-Week High | $30.93 |
| 52-Week Low | $9.23 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $4.18B |
| Net Income | $-1.82B |
| Gross Margin | 34.17% |
2 analysts cover PRGO: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $16.00.